Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Fowler Website

Daniel H. Fowler, M.D.

Selected Publications
1)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Ann. Oncol. Epub ahead of print, 2008. [Journal]
2)  Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD.
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
Blood. Epub ahead of print, 2008. [Journal]
3)  Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, Hanson JT, Wong E, Buxhoeveden N, Trepel JB, Fojo AT, Telford W, Fowler DH.
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
J. Immunol. 180: 89-105, 2008. [Journal]
4)  Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, Fowler DH.
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an IL-4/STAT6 pathway.
Blood. Epub ahead of print, 2008. [Journal]
5)  Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, Fowler DH, Varticovski L.
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.
BMC Cancer. 8: 176, 2008. [Journal]
6)  Pavletic SZ, Fowler DH.
Regulating rheumatoid arthritis via autotransplantation.
Blood. 111: 4838-9, 2008. [Journal]
7)  Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, Foley JE, Bramson JL, Fowler DH, Medin JA.
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
Mol. Ther. 16: 607-17, 2008. [Journal]
8)  Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett AJ, Bishop MR, Childs RW, Fowler DH, Pavletic SZ, Hart TC.
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
Exp. Hematol. 35: 184-92, 2007. [Journal]
9)  Subramaniam DS, Fowler DH, Pavletic SZ.
Chronic graft-versus-host disease in the era of reduced-intensity conditioning.
Leukemia. 21: 853-9, 2007. [Journal]
10)  Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA.
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production.
Blood. 109: 5399-406, 2007. [Journal]
11)  Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA.
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.
Mol. Ther. 15: 962-70, 2007. [Journal]
12)  Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR.
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
Biol. Blood Marrow Transplant. 13: 1022-30, 2007. [Journal]
13)  Liang SB, Yoshimitsu M, Poeppl A, Rasaiah VI, Cai J, Fowler DH, Medin JA.
Multiple Reduced-intensity Conditioning Regimens Facilitate Correction of Fabry Mice After Transplantation of Transduced Cells.
Mol. Ther. 15: 618-27, 2007. [Journal]
14)  Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH.
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Biol. Blood Marrow Transplant. 12: 905-18, 2006. [Journal]
15)  Hardy NM, Fowler DH, Bishop MR.
Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
Clin. Breast Cancer. 7: 87-9, 2006. [Journal]
16)  Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant. 12: 1150-60, 2006. [Journal]
17)  Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ.
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
Biol. Blood Marrow Transplant. 12: 126-37, 2006. [Journal]
18)  Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL.
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Biol. Blood Marrow Transplant. 12: 22-30, 2006. [Journal]
19)  Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH.
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.
Blood. 105: 4707-14, 2005. [Journal]
20)  Fowler D, Gress R.
Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise.
Drug Discovery Today: Disease Mechanisms. 2: 205-212, 2005. [Journal]
21)  Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR.
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
Biol Blood Marrow Transplant. 11: 593-9, 2005. [Journal]
22)  Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH.
Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Cancer Gene Ther. 12: 540-51, 2005. [Journal]
23)  Sportes C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE.
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Biol Blood Marrow Transplant. 11: 472-83, 2005. [Journal]
24)  Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, Bierer BE, Fowler DH.
Ex vivo rapamycin generates donor Th2 cells that potently inhibit GVHD and GVT effects via an IL-4 dependent mechanism.
J Immunol. 175: 5732-5743, 2005. [Journal]
25)  Fowler D, Gress R.
In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation.
Current Medicinal Chemistry-Immunology, Endocrine, and Metabolic Agents. 5: 555-564, 2005. [Journal]
26)  Fowler DH.
Shared Biology of GVHD and GVT Effects: Potential Methods of Separation.
Crit Rev Oncol Hematol. 57: 225-244, 2005. [Journal]
27)  Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
J Clin Oncol. 22: 3886-92, 2004. [Journal]
28)  Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR.
Clinical 'cytokine storm' as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.
Clin Gastroenterol Hepatol. 2: 237-245, 2004. [Journal]
29)  Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH.
Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Biol Blood Marrow Transplant. 10: 604-13, 2004. [Journal]
30)  Fowler D, Bishop M, Gress R.
Immunoablative RIST: Potential Role of Donor Th2 and Tc2 Cells.
Seminars in Oncology. 31(1): 56-67, 2004. [Journal]
31)  Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH.
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Br J Haematol. 126: 837-43, 2004. [Journal]
32)  Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH.
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
Blood. 102: 3439-46, 2003. [Journal]
33)  Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
Establishment of Early Donor Engraftment after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation to Potentiate the Graft-versus-Lymphoma Effect against Refractory Lymphomas.
Biol Blood Marrow Transplant. 9: 162-169, 2003. [Journal]
34)  Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL.
Interleukin-7 worsens graft-vs-host disease.
Blood. 4: 1082, 2002. [Journal]
35)  Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, Carter C, Read E, Gea-Benacloche J, Kasten-Sportes C, Kwak L, Wilson W, Levine B, June C, Gress R, Bishop M.
Phase I Clinical of Donor Th2 Cells after Immunoablative, Reduced Intensity Allogeneic PBSCT.
Cytotherapy. Vol. 4 (5): 429-430, 2002. [Journal]
36)  Medin JA, Fowler DH.
Post-Transduction Events in Retrovirus-Mediated Gene Transfer Involving Hematopoietic Stem Cells: Beyond Efficiency Issues.
J Cell Biochem Suppl. 38: 46-54, 2002. [Journal]
37)  Fowler D, Lavie A, Medin J, Sato T, inventor; DHHS, assignee.
Tymidylate Kinase Mutants And Uses Thereof.
Patent Pending, Filed in 2006. Application No. 11/559,757. Pending [Patent]

This page was last updated on 11/21/2008.